The tweet was deleted by the author.
But we saved everything 🙂.
Rigel Pharmaceuticals has initiated a new partnership with the Platelet Disorder Support Association (PDSA_ITP) to support ITP awareness throughout this month.
The campaign is part of #ITPawareness month, encouraging broader understanding and engagement in the immune thrombocytopenia (ITP) community. Rigel Pharmaceuticals aims to drive attention to the disease and its impact through the campaign’s outreach and the support of related causes.
View post on X Loading...
Rigel Pharmaceuticals recently announced the U.S. launch of VEPPANU, the first FDA-approved therapy in its new treatment class, according to a company statement. The firm also reported its Q2 2026 financial results and scheduled an investor webcast to discuss performance earlier this year, as detailed in its latest earnings update. These developments mark continued activity for Rigel in both its product and financial reporting efforts.